View in EDS

Naïve CD4+ T-cells and disease status at CART infusion correlate with clinical outcomes in real-world large B-cell lymphoma patients receiving second-line CAR T therapy.

Saved in:
Bibliographic Details
Title: Naïve CD4+ T-cells and disease status at CART infusion correlate with clinical outcomes in real-world large B-cell lymphoma patients receiving second-line CAR T therapy.
Authors: Schneider M; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA., Paruzzo L; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA., Stella F; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; University of Milan, Milan, Italy., Noll JH; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA., Ho M; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA., Babatunde V; Division of Nuclear Medicine Imaging and Therapy, Hospital of the University of Pennsylvania, Philadelphia, PA, USA., Ho B; Division of Nuclear Medicine Imaging and Therapy, Hospital of the University of Pennsylvania, Philadelphia, PA, USA., Devi P; Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA., Chong EA; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA., Barta SK; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA., Nasta SD; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA., Svoboda J; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA., Carter J; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA., Cook MR; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA., Hossain NM; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Thomas CJ; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA., Patel V; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA., de Souza VB; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA., Alkhatib MH; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA., Li Z; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA., Tan M; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA., Michener P; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA., Guruprasad P; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA., Imparato A; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; Department of Biomedical Sciences, Humanitas University, Milan, Italy., Carturan A; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA., Porazzi P; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA., Fraietta JA; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia, Philadelphia, PA, USA., Schuster SJ; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA., Maillard I; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Division of Hematologic Malignancies & Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Ruella M; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA. mruella@upenn.edu.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA. mruella@upenn.edu.; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. mruella@upenn.edu.; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. mruella@upenn.edu., Landsburg DJ; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA. daniel.landsburg@pennmedicine.upenn.edu.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA. daniel.landsburg@pennmedicine.upenn.edu.; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. daniel.landsburg@pennmedicine.upenn.edu.
Source: Nature communications [Nat Commun] 2026 May 15; Vol. 17 (1). Date of Electronic Publication: 2026 May 15.
Publication Type: Journal Article
Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42140929
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Naïve CD4<superscript>+</superscript> T-cells and disease status at CART infusion correlate with clinical outcomes in real-world large B-cell lymphoma patients receiving second-line CAR T therapy.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Schneider+M%22">Schneider M</searchLink>; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA.<br /><searchLink fieldCode="AU" term="%22Paruzzo+L%22">Paruzzo L</searchLink>; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Stella+F%22">Stella F</searchLink>; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; University of Milan, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Noll+JH%22">Noll JH</searchLink>; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Ho+M%22">Ho M</searchLink>; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Babatunde+V%22">Babatunde V</searchLink>; Division of Nuclear Medicine Imaging and Therapy, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Ho+B%22">Ho B</searchLink>; Division of Nuclear Medicine Imaging and Therapy, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Devi+P%22">Devi P</searchLink>; Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Chong+EA%22">Chong EA</searchLink>; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Barta+SK%22">Barta SK</searchLink>; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Nasta+SD%22">Nasta SD</searchLink>; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Svoboda+J%22">Svoboda J</searchLink>; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Carter+J%22">Carter J</searchLink>; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Cook+MR%22">Cook MR</searchLink>; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Hossain+NM%22">Hossain NM</searchLink>; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Thomas+CJ%22">Thomas CJ</searchLink>; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Patel+V%22">Patel V</searchLink>; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22de+Souza+VB%22">de Souza VB</searchLink>; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Alkhatib+MH%22">Alkhatib MH</searchLink>; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Li+Z%22">Li Z</searchLink>; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Tan+M%22">Tan M</searchLink>; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Michener+P%22">Michener P</searchLink>; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Guruprasad+P%22">Guruprasad P</searchLink>; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Imparato+A%22">Imparato A</searchLink>; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; Department of Biomedical Sciences, Humanitas University, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Carturan+A%22">Carturan A</searchLink>; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Porazzi+P%22">Porazzi P</searchLink>; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Fraietta+JA%22">Fraietta JA</searchLink>; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Schuster+SJ%22">Schuster SJ</searchLink>; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Maillard+I%22">Maillard I</searchLink>; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Division of Hematologic Malignancies & Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Ruella+M%22">Ruella M</searchLink>; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA. mruella@upenn.edu.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA. mruella@upenn.edu.; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. mruella@upenn.edu.; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. mruella@upenn.edu.<br /><searchLink fieldCode="AU" term="%22Landsburg+DJ%22">Landsburg DJ</searchLink>; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA. daniel.landsburg@pennmedicine.upenn.edu.; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA. daniel.landsburg@pennmedicine.upenn.edu.; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. daniel.landsburg@pennmedicine.upenn.edu.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101528555%22">Nature communications</searchLink> [Nat Commun] 2026 May 15; Vol. 17 (1). <i>Date of Electronic Publication: </i>2026 May 15.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Pub%2E+Group%22">Nature Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101528555 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2041-1723 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220411723%22">20411723 </searchLink><i>NLM ISO Abbreviation: </i>Nat Commun <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42140929
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41467-026-71710-7
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Naïve CD4+ T-cells and disease status at CART infusion correlate with clinical outcomes in real-world large B-cell lymphoma patients receiving second-line CAR T therapy.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Schneider M
      – PersonEntity:
          Name:
            NameFull: Paruzzo L
      – PersonEntity:
          Name:
            NameFull: Stella F
      – PersonEntity:
          Name:
            NameFull: Noll JH
      – PersonEntity:
          Name:
            NameFull: Ho M
      – PersonEntity:
          Name:
            NameFull: Babatunde V
      – PersonEntity:
          Name:
            NameFull: Ho B
      – PersonEntity:
          Name:
            NameFull: Devi P
      – PersonEntity:
          Name:
            NameFull: Chong EA
      – PersonEntity:
          Name:
            NameFull: Barta SK
      – PersonEntity:
          Name:
            NameFull: Nasta SD
      – PersonEntity:
          Name:
            NameFull: Svoboda J
      – PersonEntity:
          Name:
            NameFull: Carter J
      – PersonEntity:
          Name:
            NameFull: Cook MR
      – PersonEntity:
          Name:
            NameFull: Hossain NM
      – PersonEntity:
          Name:
            NameFull: Thomas CJ
      – PersonEntity:
          Name:
            NameFull: Patel V
      – PersonEntity:
          Name:
            NameFull: de Souza VB
      – PersonEntity:
          Name:
            NameFull: Alkhatib MH
      – PersonEntity:
          Name:
            NameFull: Li Z
      – PersonEntity:
          Name:
            NameFull: Tan M
      – PersonEntity:
          Name:
            NameFull: Michener P
      – PersonEntity:
          Name:
            NameFull: Guruprasad P
      – PersonEntity:
          Name:
            NameFull: Imparato A
      – PersonEntity:
          Name:
            NameFull: Carturan A
      – PersonEntity:
          Name:
            NameFull: Porazzi P
      – PersonEntity:
          Name:
            NameFull: Fraietta JA
      – PersonEntity:
          Name:
            NameFull: Schuster SJ
      – PersonEntity:
          Name:
            NameFull: Maillard I
      – PersonEntity:
          Name:
            NameFull: Ruella M
      – PersonEntity:
          Name:
            NameFull: Landsburg DJ
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 15
              M: 05
              Text: 2026 May 15
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 2041-1723
          Numbering:
            – Type: volume
              Value: 17
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Nature communications
              Type: main
ResultId 1